comprehensive -WSS

comprehensive

author：entertainment 2025-10-02 11:38:07 - browse：7885

The FDA building -- First Opinion coverage from STAT — Adobe

The clearance of a first-of-its-kind cancer treatment made by Amgen is on shakier ground following a Food and Drug Administration advisory committee meeting Thursday.

Regulatory advisers voted 10-2 that the data on the company’s drug Lumakras, a treatment for lung cancer, could not be properly assessed. Lumakras targets a specific mutation to a protein called KRAS, which is one of the most common genetic mutations in cancer.

The vote comes as Amgen is hoping to convert a conditional approval for the drug to a full approval based on a 345-person study called CodeBreaK 200, in which Lumakras met the primary endpoint, delaying tumor growth approximately five weeks longer than the standard of care medication, docetaxel. The drug didn’t extend patients’ overall survival.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Sports medicine is finally prioritizing gender equality
Next article： GOP inquiry over gain

WSS

Change Healthcare outage fallout shows need for new oversight

Newly formed Hurricane Beatriz sweeps close to Mexico's southwest Pacific coast

Tuskegee Airman Raymond Cassagnol dies at 102

President Biden's budget: Here's what you might have missed

Acadia's Nuplazid fails as schizophrenia medicine in Phase 3 study

UnitedHealth wins $3.3 billion takeover of Amedisys

leisure time

comprehensive

Wikipedia

New air purifier tech could be key to improving indoor air quality

Steward Health Care Massachusetts hospitals face fiscal disaster

What does generative AI mean for health care? We asked experts

Wildfire smoke map: Which US cities are forecast to be impacted by fires burning in Canada

The high cost of giving birth even with insurance

Illumina to lay off 10% of research and development team

Sports medicine is finally prioritizing gender equality

Brazil's Jair Bolsonaro is barred from running for office until 2030

After affirmative action ruling, medical educators look to 'holistic review'

HHS secretary Becerra pressed on Change HealthCare cyberattack

hotspot

Medicare coverage of Wegovy, once blocked, now looks possible

The sun may be out, but guns are not. A lawsuit challenges a new gun ban on Hawaii beaches

First U.S. drug developed to treat liver disease MASH is approved

HHS secretary Becerra pressed on Change HealthCare cyberattack

Boston's new lab space is opening empty

Amid AI frenzy, a top HHS official's quest to create safeguards

leisure time

Wikipedia

explore

Wikipedia